Welcome to our dedicated page for Astria Therapeutics news (Ticker: ATXS), a resource for investors and traders seeking the latest updates and insights on Astria Therapeutics stock.
Astria Therapeutics, Inc. (NASDAQ: ATXS) generates news primarily as a clinical‑stage biopharmaceutical company focused on allergic and immunologic diseases. Company updates center on its lead investigational therapy navenibart (STAR‑0215), a monoclonal antibody inhibitor of plasma kallikrein in development for hereditary angioedema (HAE), and on STAR‑0310, an investigational OX40 antagonist in development for atopic dermatitis.
News items about Astria often highlight progress in its clinical programs. For navenibart, this includes announcements on the ALPHA‑STAR Phase 1b/2 trial results in HAE patients, the global ALPHA‑ORBIT Phase 3 randomized, double‑blind, placebo‑controlled trial, and the ORBIT‑EXPANSE long‑term extension trial where all participants receive navenibart on every‑three‑month or every‑six‑month dosing schedules. Press releases have described attack‑rate reductions, safety and tolerability findings, and patient‑reported quality‑of‑life measures, as well as enrollment milestones and trial site activations across multiple regions.
Coverage also includes early‑stage results for STAR‑0310, where Astria has reported Phase 1a data in healthy subjects, including extended half‑life, durable cytokine inhibition over 16 to 20 weeks, and the absence of antibody‑dependent cellular cytotoxicity‑related side effects in the data presented. These updates are frequently tied to scientific and medical conferences in allergy and dermatology.
In addition, Astria’s news flow features corporate and strategic developments such as the definitive merger agreement with BioCryst Pharmaceuticals, Inc., under which BioCryst has agreed to acquire Astria for a mix of cash and stock, and a license agreement with Kaken Pharmaceutical Co., Ltd. for navenibart rights in Japan. Investors following ATXS news can expect a mix of clinical trial readouts, regulatory and collaboration announcements, financial updates, and transaction‑related disclosures.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the promotion of Andrea Matthews to Chief Business Officer, elevating her role to enhance the company’s strategic growth. Matthews, who has nearly nine years with Astria, is tasked with overseeing Corporate Strategy, Business Development, Investor Relations, Corporate Communications, and Patient Advocacy. Her leadership is expected to drive the development of STAR-0215, a monoclonal antibody in clinical trials for treating hereditary angioedema. CEO Jill C. Milne highlighted Matthews' contributions to the company’s pivotal developments. The company focuses on creating impactful therapies for rare allergic and immunological diseases.
Astria Therapeutics, Inc. (NASDAQ:ATXS) announced the grant of stock options for 39,300 shares of common stock on April 3, 2023. This grant, made under the 2022 Inducement Stock Incentive Plan, targets new employees as per Nasdaq Listing Rule 5635(c)(4). The options will have an exercise price of $12.93, equivalent to the closing stock price on the grant date. Vesting occurs over four years, with 25% vesting after the first anniversary and the remainder vesting monthly for 36 months, contingent upon continued employment. Astria focuses on rare and niche immunological diseases with its lead program, STAR-0215, targeting hereditary angioedema.
Astria Therapeutics, Inc. (NASDAQ:ATXS) provided a corporate update and financial results for Q4 2022 and the full year. The company is advancing STAR-0215 for hereditary angioedema (HAE) treatment, with promising Phase 1a results showing a potential half-life of up to 117 days. The ALPHA-STAR Phase 1b/2 trial is underway, with proof-of-concept results expected in mid-2024. As of December 31, 2022, Astria reported cash and short-term investments of $226M, ensuring operational funding through mid-2025. The net loss for Q4 was $13.3M, reflecting a slight increase from the previous year.
Astria Therapeutics, Inc. (NASDAQ:ATXS) will announce its fourth quarter and full year 2022 financial results before the Nasdaq Global Market opens on March 22, 2023. CEO Jill C. Milne, Ph.D., will lead a conference call and webcast at 8:30am ET to discuss these results and provide updates on corporate developments. The company's lead program, STAR-0215, is in clinical development for hereditary angioedema. Interested parties can access the webcast through the Astria website. The announcement aims to inform investors and stakeholders of the company’s performance and future outlook.